Skip to main content

Table 1 Clincopathological features of the study populations

From: Development of nomograms to predict axillary lymph node status in breast cancer patients

  Training Cohort Validation Cohort
N % N %
Year Of Diagnosis
 2010 47,203 47.38 0 0.00
 2011 52,415 52.62 0 0.00
 2012 0 0.00 50,965 50.05
 2013 0 0.00 50,869 49.95
Age Group
 Age < =50Yrs 23,231 23.32 22,203 21.80
 50-60Yrs 25,967 26.07 26,600 26.12
  > 60Yrs 50,420 50.61 53,031 52.08
Location Of Lesions
 UIQ 18,891 18.96 19,939 19.58
 UOQ 53,372 53.58 54,995 54.00
 LOQ 11,425 11.47 11,776 11.56
 LIQ 9086 9.12 8776 8.62
 Central 6844 6.87 6348 6.23
Race
 White 84,246 84.57 85,967 84.42
 African American 10,334 10.37 10,429 10.24
 Others 4184 4.20 4568 4.49
 Unknown 854 0.86 870 0.85
T-Stage
 T1a 69,375 69.64 71,740 70.45
 T2 27,675 27.78 27,528 27.03
 T3 2568 2.58 2566 2.52
N-Stage
 N0 73,662 73.94 76,954 75.57
 N1 19,724 19.80 19,362 19.01
 N2 4313 4.33 3829 3.76
 N3 1919 1.93 1689 1.66
Histology
 IDC 75,974 76.27 77,806 76.40
 ILC 8582 8.61 9795 9.62
 IDC & ILC 5005 5.02 5076 4.98
 IDC & Others 3359 3.37 3390 3.33
 IMC 1849 1.86 1857 1.82
 Others 4849 4.87 3910 3.84
Grade
 I 25,663 25.76 26,780 26.30
 II 43,908 44.08 45,673 44.85
 III 29,420 29.53 28,304 27.79
 Others/NA 627 0.63 1077 1.06
Estrogen Receptor
 Negative 15,746 15.81 14,902 14.63
 Positive 83,872 84.19 86,932 85.37
Progesterone Receptor
 Negative 25,080 25.18 23,426 23.00
 Positive 74,538 74.82 78,408 77.00
Her2
 Negative 87,670 88.01 92,043 90.39
 Positive 11,948 11.99 9791 9.61
Lymphovascular Invasion
 Not Present 80,657 80.97 83,226 81.73
 Present 18,961 19.03 18,608 18.27
Charlson-Deyo Score
 0 83,641 83.96 84,466 82.94
 1 13,297 13.35 14,319 14.06
 2 2680 2.69 3049 2.99
Breast Surgery
 BCS + RT 64,552 64.80 66,480 65.28
 Mastectomyb 35,066 35.20 35,354 34.72
  1. NCDB national cancer database, Yrs years, HER2 human epidermal growth factor receptor 2, BCS breast-conserving surgery, RT radiotherapy, LIQ lower-inner quadrant, LOQ lower-outer quadrant, UIQ Upper-inner quadrant, UOQ Upper-outer quadrant, NA not available, IDC infiltrating ductal carcinoma, ILC infiltrating lobular carcinoma, IMC invasive mucinous carcinoma;
  2. aDCIS with micrometastasis (T1mic) were included in T1
  3. bSubcutaneous mastectomy and reconstruction surgery were included